This is a working overview of bioavailability, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Eurogentec is a biotechnology supplier, based in Belgium, that specializes in genomics and proteomics kits, reagents, and certain biologics. It was founded in 1985 as a spin-off from the University of Liège. Eurogentec operates two licensed contract manufacturing organization facilities in Belgium which produce custom biologic and oligonucleotide products mainly for European pharmaceutical companies, but also holds a license from the U.S. FDA to export a commercial protein product to the U.S.. These products are used to diagnose and treat various conditions.
Main sections: §§ Signaling after internalisation and Conformational states The persistent signaling that is present after internalisation could be the reason for ineffectivity of common KOR antagonists given that they work on receptor's outer membrane. Antagonists also tend to preserves conformation states; in this case presumably "alternative state" due to the endogenous bias for the β-arrestin signaling during stress responses.
Peak-to-trough ratio (PTR), also known as peak-to-trough variation or peak-to-trough fluctuation, is a parameter in pharmacokinetics which is defined as the ratio of Cmax (peak) concentration and Cmin (trough) concentration over a dosing interval for a given drug. A drug with an elimination half-life of 24 hours taken once per day will have a peak-to-trough ratio of approximately 2. Peak-to-trough ratio depends on half-life and dosing interval, with longer half-lives and shorter dosing intervals giving smaller ratios.
Sources: en.wikipedia.org
Maduro responded that Bisessar's offer was tantamount to declaring war on Venezuela, and threatened both countries with retaliation if Trinidad went through with its offer. Bisessar later praised the deployment and the 2 September strike, saying "the US military should kill [all drug traffickers] violently". Foreign Minister of Barbados Kerrie Symmonds said that the foreign ministers of CARICOM wrote to US Secretary of State Marco Rubio asking that military operations in the Caribbean not be conducted without prior notice or explanation. The deployment was endorsed by the government of Guyana, two-thirds of its territory being claimed by Venezuela, with Guyana's vice president and former president Bharrat Jagdeo telling The Financial Times "You cannot trust Maduro." According to Havana Times, the deployment "reignited tensions and divided positions in the region", with "the Cuba–Venezuela–Nicaragua axis" calling it an "imperialist offensive", and other countries "harden[ing] their stance against Maduro and the Cartel of the Soles." The Commander of the Cayman Islands Coast Guard, Robert Scotland, stated that the US strikes would "send a very clear message to those entities who have been designated as narco-terrorists, and should serve as a strong deterrent to anyone who seeks to engage in the illicit trafficking of drugs and firearms within our region".
) without multiplying by 1000 unless the basic SI unit of mol/s were to be used, which would otherwise require the molar mass to be converted to kg/mol. For convenience in avoiding conversions in the imperial (or US customary units), some engineers adopted the pound-mole (notation lb-mol or lbmol), which is defined as the number of entities in 12 lb of 12C. One lb-mol is equal to 453.59237 g‑mol, which is the same numerical value as the number of grams in an international avoirdupois pound. Greenhouse and growth chamber lighting for plants is sometimes expressed in micromoles per square metre per second, where 1 mol photons ≈ 6.02×1023 photons. The obsolete unit einstein is variously defined as the energy in one mole of photons and also as simply one mole of photons.
Flupentixol/melitracen (trade name Deanxit) is a combination of two psychoactive agents flupentixol and melitracen. It is designed for short term usage only. It is produced by Lundbeck. Flupentixol is a thioxanthene antipsychotic, and melitracen is a tricyclic antidepressant. Low dose Flupentixol (0.5 mg-3 mg) has antidepressant and anti-anxiety effects, while melitracen has antidepressant effect. The mixture of the two components is used to treat mild to moderate mental disorders. Flupentixol acts as a dopamine 1 and 2 receptor antagonist and melitracen acts in similar way to other tricyclic antidepressants blocking the reuptake of serotonin and norepinephrine in presynaptic terminals.
Sources: en.wikipedia.org
Hadacidin, and hadacidin analogues, have anticancer activity and activity against adenylosuccinate synthetase. Hadacidin is the simplest known naturally occurring hydroxamic acid. The hydroxylamino group is frequently donated by a hydroxylamino acid such as 8-N-hydroxyornithine of the siderochromes. This compound, first isolated and characterized by Kaczka et al. in 1962, seemed well suited for a study of the route of hydroxamic acid biosynthesis. The hydroxamate bond may be considered to be a peptide bond with an oxygen atom on the amide nitrogen, but there is no a priori reason to decide whether the oxygen atom is introduced before or after the formation of the amide bond. In the latter case, formylglycine would be an intermediate in hadacidin biosynthesis. N-Hydroxylation of an amide bond was reported by Cramer et al. (1960), who found that N-hydroxy-2-acetylaminofluorene was formed in the intact rat upon administration of 2-acetylaminofluorene. Nevertheless, this finding cannot be considered direct proof of N-hydroxylation of an amide bond because, as the authors point out, the acetyl group is labile in their experiments, and hydroxylation of the amino group might have occurred. Glycine, formate, and the 2-carbon of serine were all found to be very quickly incorporated into hadacidin during its synthesis by Penicillium aurantioviolaceum.
. This Laplacian term can be interpreted as the difference between the velocity at a point and the mean velocity in a small surrounding volume. This implies that – for a Newtonian fluid – viscosity operates as a diffusion of momentum, in much the same way as the heat conduction. In fact neglecting the convection term, incompressible Navier–Stokes equations lead to a vector diffusion equation (namely Stokes equations), but in general the convection term is present, so incompressible Navier–Stokes equations belong to the class of convection–diffusion equations. In the usual case of an external field being a conservative field:
Netherlands: Prime Minister Dick Schoof stated that the Dutch cabinet was "closely following the developments in the Caribbean region and the situation in Venezuela following the US attacks," saying that "safety in the region is of great importance to Aruba, Curaçao and Bonaire." Foreign Affairs Minister David van Weel stated that "The Kingdom of the Netherlands does not recognise the Maduro regime and calls for a swift return to democracy. The Netherlands urges all parties to prevent further escalation and to adhere to international law." Norway: Minister of Foreign Affairs Espen Barth Eide stated that even though Norway does not recognize the legitimacy of Maduro's presidency, the American military operation marked "a grave escalation of an already highly volatile situation" and that it was "not in accordance with international law." Poland: Prime Minister Donald Tusk stated that the "U.S. strike on Venezuela affects the entire world," and that he hoped that 2026 would not be more eventful than 2025. Portugal: Prime Minister Luís Montenegro stated that the Portuguese government is "focused on the future and on the restoration of a full democracy in which Venezuelans can freely choose their future." and that the government is "taking note of President Trump and the role of the United States in promoting a stable, peaceful, democratic, and inclusive transition in Venezuela as swiftly as possible.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.